Prior to joining Hatteras, Mr. Ingram was Chief Executive Officer and Chairman of GlaxoWellcome. Mr. Ingram co-led the merger and integration that formed GlaxoSmithKline. Upon reaching mandatory retirement age of 60, Mr. Ingram served as the Vice Chairman, Pharmaceuticals at GSK before becoming Strategic Advisor to the CEO of GlaxoSmithKline Plc. Mr. Ingram is Chairman of the boards of Novan, Inc., a late-stage pharmaceutical company focused on dermatology, and the Board of BioCryst Pharmaceuticals, Inc. He recently retired as the Chairman the Board of Cree, Inc. and the Board of Selenity Pharmaceuticals Inc. In 2013, Bob received the NACD B. Kenneth West Lifetime Achievement Award from the National Association of Corporate Directors.
At the request of US President George H.W. Bush, Bob formed and chaired the CEO Roundtable on Cancer. In 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board. He accepted his third Presidential appointment most recently in 2019, when he was appointed by President Donald J. Trump’s administration to serve on the Presidential Cancer Panel. In 2014, Bob received the North Carolina Award for public service, the highest civilian honor the state can bestow on an individual. Bob currently serves on the board of the Research Triangle Foundation of North Carolina, the Research Triangle Institute, and is Chairman of the GlaxoSmithKline Foundation.
Robert graduated from Eastern Illinois University with a B.S. in Business Administration.